The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2014.07.004PMID 25026637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant chemotherapy

  2013cited by this paper
• Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.

  2013cited by this paper
• An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

  2012influential reference
• Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?

  2012cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010influential reference
• Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

  2007cited by this paper
• Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.

  2006cited by this paper
• Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer

  2006cited by this paper
• Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2006cited by this paper
• Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer:A Gynecologic Oncology Group study

  2006cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?

  2001cited by this paper
• Adjuvant chemotherapy

  1978cited by this paper

• The prognosis impact of NACT-IDS and PDS in advanced ovarian cancer: a systematic review and meta-analysis

  2025cites this paper
• The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.

  2025cites this paper
• Prognostic Relevance of Clinical and Tumor Mutational Profile in High-Grade Serous Ovarian Cancer

  2025cites this paper
• The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database

  2025cites this paper
• The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment

  2025cites this paper
• Debulking Surgery, Survival Outcomes, and Rehabilitation in Advanced Ovarian Cancer: A Narrative Review

  2025cites this paper
• Neoadjuvant Chemotherapy, Case Volume, and Mortality in Advanced Ovarian Cancer.

  2025cites this paper
• Comparative Retrospective Analysis of Ovarian Cancer Treatment Outcomes: Neoadjuvant Therapy with and without Surgical Intervention

  2024cites this paper
• Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.

  2024cites this paper
• Clinical Investigation into Survival Outcomes Among Stage IV Epithelial Ovarian Cancer Patients Receiving Curative Treatment: Indian Setting

  2024cites this paper
• Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?

  2024cites this paper
• The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives

  2024cites this paper
• The hyperthermic intraperitoneal chemotherapy in the treatment of advanced ovarian cancer - new trend, or a dead end?

  2024cites this paper
• Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?

  2023cites this paper
• Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

  2023cites this paper
• The role of PARP inhibitor combination therapy in ovarian cancer

  2023cites this paper
• Prognostic value of the ascites characteristics in pseudomyxoma peritonei originating from the appendix

  2023cites this paper
• MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis

  2023cites this paper
• A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer

  2023cites this paper
• Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.

  2022cites this paper
• Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes

  2022cites this paper
• The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery

  2022cites this paper
• A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations—Does One Model Type Fit All?

  2022cites this paper
• Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction

  2022cites this paper
• Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer

  2022cites this paper
• Comparative Study of Laparascopy Scoring and Laparatomy Staging in Advance Ovarian Cancer

  2022cites this paper
• Achieving Complete Radiological and Bio-Chemical Response as a Predictor of Long-Term Survival in Stage IV Epithelial Ovarian Cancer

  2021cites this paper
• Optimal Strategies for Therapy and Screening

  2021cites this paper
• Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment

  2021cites this paper
• Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer.

  2021cites this paper
• Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening

  2021influential citation
• A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study

  2020cites this paper
• miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer

  2020cites this paper
• Ex Vivo Assessment of Tumor-Targeting Fluorescent Tracers for Image-Guided Surgery

  2020cites this paper
• Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research

  2020cites this paper
• Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: a multicentre study of the FRANCOGYN research group.

  2020cites this paper
• PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials

  2020cites this paper
• Outcome quality standards in advanced ovarian cancer surgery

  2020cites this paper
• CA125 and Ovarian Cancer: A Comprehensive Review

  2020cites this paper
• The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10‐year survival from advanced ovarian cancer

  2020cites this paper
• Advanced stage ovarian cancer patients with neoadjuvant chemotherapy suffered worse recurrence free survival

  2020cites this paper
• OTT_A_239425 2887..2897

  2020cites this paper
• Does Neoadjuvant Chemotherapy Impact Prognosis in Advanced-Stage Epithelial Ovarian Cancer Optimally Debulked at Surgery?

  2019cites this paper
• CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.

  2019cites this paper
• [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

  2019cites this paper
• Computational Modeling of Ovarian Cancer Reveals Optimal Strategies for Therapy and Screening

  2019cites this paper
• Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer

  2019cites this paper
• Supervivencia tras cirugía citorreductora de máximo esfuerzo y quimioterapia basada en platino en pacientes con cáncer epitelial de ovario, carcinoma de trompa de Falopio y carcinomatosis peritoneal primaria: experiencia de un Hospital Público Universitario en España

  2019cites this paper
• A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.

  2019cites this paper
• A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.

  2019cites this paper
• Survival after maximum effort cytoreductive surgery and platinum-based chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma and primary peritoneal carcinomatosis: Experience of a Public University Hospital in Spain

  2019cites this paper
• A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.

  2019cites this paper
• Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

  2019cites this paper
• Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

  2019cites this paper
• Optimising patient selection to improve outcome in advanced ovarian cancer

  2019cites this paper
• Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression.

  2019cites this paper
• The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.

  2019cites this paper
• Racial Differences in Survival From Epithelial Ovarian Cancer Are Associated With Stage at Diagnosis and Use of Neoadjuvant Therapy: A 10-Year Single-Institution Experience With a Racially Diverse Urban Population

  2018cites this paper
• Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study

  2018cites this paper
• No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands.

  2018cites this paper
• In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery

  2018cites this paper
• Image‐guided surgery in cancer: A strategy to reduce incidence of positive surgical margins

  2018cites this paper
• Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.

  2018cites this paper
• Molybdenum cluster loaded PLGA nanoparticles: An innovative theranostic approach for the treatment of ovarian cancer

  2018cites this paper
• Improving quality of care for patients with ovarian and endometrial cancer

  2018cites this paper
• Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study

  2018cites this paper
• Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced Ovarian Cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery

  2018cites this paper
• Primary Debulking Surgery Versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals

  2018cites this paper
• Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients

  2018cites this paper
• Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.

  2018cites this paper
• Is There a Future for Ovarian Cancer Screening?

  2018cites this paper
• Surgical and Medical Management of Epithelial Ovarian Cancer

  2018cites this paper
• Ovarian cancer with pleural and lung metastasis in Dr. Soetomo Hospital, Surabaya, Indonesia, in 2014-2015

  2018cites this paper
• Role hypertermické intraperitoneální chemoterapie v léčbě pokročilého a recidivujícího ovariálního karcinomu

  2017cites this paper
• The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies

  2017cites this paper
• Real-world evidence in the treatment of ovarian cancer

  2017cites this paper
• Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?

  2017cites this paper
• The immune environment in ovarian cancer 1 2 3 4 5 6 7 8

  2017cites this paper
• A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy

  2017cites this paper
• Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.

  2017cites this paper
• Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.

  2017cites this paper
• Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis

  2017cites this paper
• Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients.

  2017cites this paper
• Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.

  2017cites this paper
• Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study.

  2017cites this paper
• Surgery for advanced epithelial ovarian cancer.

  2017cites this paper
• Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer

  2017cites this paper
• Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis

  2017cites this paper
• Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?

  2017cites this paper
• Tuulia Vallius: NOVEL PREDICTORS OF RESPONSE AND OUTCOME IN ADVANCED EPITHELIAL OVARIAN CANCER

  2017cites this paper
• HOW TO ASSESS QUALITY OF SURGERY IN OVARIAN CANCER?

  2017cites this paper
• Role hypertermické intraperitoneální chemoterapie v léčbě pokročilého a recidivujícího ovariálního karcinomu

  2017cites this paper
• Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy

  2016cites this paper
• Ovarian cancer: is chemotherapy before surgery the way forward?

  2016cites this paper
• Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.

  2016cites this paper
• Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.

  2016cites this paper
• Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.

  2016cites this paper
• Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.

  2016cites this paper
• The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

  2016cites this paper
• Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer.

  2016cites this paper